Date: 2016-03-11
Type of information: Collaboration agreement
Compound: therapeutic vaccines
Company: OncoQR ML (Austria) TYG Oncology (UK)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: therapeutic vaccine/immunotherapy product
Disease: gastrointestinal cancers
Details: * On March 11, 2016, TYG oncology, a UK biotechnology company specializing in hormone neutralization therapy for gastrointestinal cancers, and OncoQR ML GmbH, an Austrian biotechnology company specializing in developing therapeutic vaccines against oncological and infectious disease targets using the S-TIR™ technology platform, have expanded their collaboration to develop additional therapeutic vaccines against gastrointestinal cancers. The parties have agreed on confidentiality regarding the general terms and financial details of the transaction. TYG oncology’s lead vaccine candidate is TYG100, a novel immunotherapy based on the S-TIR™ technology platform, targeted against pancreatic and other gastrointestinal cancers for the clinically validated target gastrin (G17). With the expansion of the collaboration, TYG oncology has also been awarded the exclusive, unlimited right to exploit the S-TIR™ technology for other forms of gastrin and related gastrointestinal targets. TYG oncology is now seeking commercial partners for the fast track clinical development of its Orphan Drug TYG100 against pancreatic cancer and gastroesophageal cancer.
Financial terms:
Latest news:
